EXTON, Pa., Oct. 18, 2004 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) will host a conference call with investors and webcast to discuss the company's agreement to acquire all rights to the Vancocin brand in the U.S., from Eli Lilly and Company (Lilly) (NYSE:LLY). During the call, ViroPharma senior management will discuss, among other topics, the significance of the acquisition, the financial implications to the company, and the addressable market for the product.
The conference call and webcast will be held Tuesday, October 19th at 10:00 a.m. Eastern Time. To participate in the call, please dial (800) 992-7413 (domestic) and (801) 303-7424 (international). After placing the call, please tell the operator you wish to join the ViroPharma investor conference call.
In addition, a live webcast of the call can be accessed via ViroPharma's website at http://www.viropharma.com. Windows Media or Real Player will be needed to access the webcast.
If you are unable to attend the live conference call and webcast, an audio archive will be available at the same address until December 17, 2004.
About ViroPharma Incorporated
ViroPharma Incorporated is committed to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma is currently focused on drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV).